<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Individuals with <z:e sem="disease" ids="C0221013" disease_type="Disease or Syndrome" abbrv="">systemic mast cell disease</z:e> (SMCD) may develop various hematologic abnormalities, including cytopenias, myeloproliferative or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, lymphoproliferative syndromes, and primary or secondary <z:hpo ids='HP_0001909'>leukemias</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Management of those patients is often complicated by their associated hematologic abnormalities </plain></SENT>
<SENT sid="2" pm="."><plain>In the case of non-malignant hematologic syndromes, the approach to management is supportive </plain></SENT>
<SENT sid="3" pm="."><plain>At present, overt <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> are managed with traditional chemotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>The presence of <z:hpo ids='HP_0001909'>leukemia</z:hpo> in patients with <z:e sem="disease" ids="C0024899" disease_type="Disease or Syndrome" abbrv="">mast cell disease</z:e> usually indicates a grave prognosis </plain></SENT>
</text></document>